PrecisionLife has joined the BioIndustry Association (BIA), the award-winning trade association for innovative life sciences in the UK.

Established over a quarter of a century ago at the infancy of biotechnology, the goal of the BIA is to secure the UK’s position as a global hub for innovative research and commercialisation. They are the only national trade association representing the UK bioscience sector.

PrecisionLife co-founder and CEO, Dr Steve Gardner said “as a life science business with innovation at its heart, we want to grow sustainably to be successful.

“We’re delighted therefore to have joined the BIA; an organisation with a broad membership that includes start-ups, universities and forward-thinking pharma companies.

“For us, the appeal is simple; the BIA works to bring people together across a range of life science issues, doing much to support and represent UK biotech on the global stage.

“The BIA share our vision for enabling world-leading research that delivers real healthcare solutions and make a genuine difference to real people’s lives.”

With offices in the UK, USA, Denmark and Poland, PrecisionLife works internationally with pharma and biotech businesses, healthcare and disease charities, to create novel therapies and diagnostics that will help treat and manage conditions to enable people to lead normal lives.

PrecisionLife operates a scalable early-stage partnering model which develops and out-licenses multiple novel in vitro/in vivo validated assets. These assets are supported by comprehensive biological data packages, and are fully annotated and pre-selected to meet known drug discovery and drug repurposing criteria.